JFL Life Sciences
JFLLIFE NSE
JFL Life Sciences
HealthcareNSE: JFLLIFE Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹70.28 Cr
Volatility
Moderate
P/E Ratio
10.34
EBITDA
₹11.71 Cr
Return on Equity
10.54%
Debt to Equity
0.48
Book Value
₹13.9
52W High
₹15.4
52W Low
₹8.55
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company is expected to give good quarter
- Company has delivered good profit growth of 64.0% CAGR over last 5 years
- Company's working capital requirements have reduced from 136 days to 103 days
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.2% over last 3 years.
Growth Rate
Revenue Growth
60.02% higher than
3Y
Net Income Growth
53.33% higher than
3Y
Cash Flow Change
-142% lower than
3Y
ROE
13.58% higher than
3Y
ROCE
38.94% higher than
3Y
EBITDA Margin (Avg.)
-10.9% higher than
3Y
Quarterly Results
| Particulars | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.7 | 9.54 | 39.51 | 21.25 | 11.73 | 11.59 | 29.91 | 26.84 | 63.05 | 11.1 |
| Expenses | 20.15 | 6.48 | 37.1 | 19.9 | 10.35 | 9.66 | 27 | 23.49 | 59.54 | 9.01 |
| Operating Profit | 1.55 | 3.06 | 2.41 | 1.35 | 1.38 | 1.93 | 2.91 | 3.35 | 3.51 | 2.09 |
| OPM % | 7.14% | 32.08% | 6.1% | 6.35% | 11.76% | 16.65% | 9.73% | 12.48% | 5.57% | 18.83% |
| Other Income | 0.02 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.04 | 0.02 |
| Interest | 0.09 | 0.26 | 0.27 | 0.2 | 0.33 | 0.24 | 0.44 | 0.38 | 1.03 | 0.3 |
| Depreciation | 0.11 | 0.24 | 0.24 | 0.16 | 0.36 | 0.26 | 0.27 | 0.27 | 0.27 | 0.32 |
| PBT | 1.37 | 2.56 | 1.9 | 0.99 | 0.69 | 1.43 | 2.21 | 2.71 | 2.25 | 1.49 |
| Tax % | 13.14% | 25.39% | 23.16% | 25.25% | 86.96% | 48.25% | 10.86% | 25.09% | 26.22% | 25.5% |
| Net Profit | 1.19 | 1.91 | 1.45 | 0.74 | 0.08 | 0.75 | 1.97 | 2.02 | 1.66 | 1.11 |
| EPS in Rs | 0.18 | 0.29 | 0.22 | 0.11 | 0.01 | 0.11 | 0.3 | 0.31 | 0.25 | 0.17 |
Profit & Loss
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 32 | 30 | 33 | 34 | 43 | 47 | 82 | 131 | 131 |
| Expenses | 30 | 28 | 31 | 28 | 39 | 42 | 74 | 120 | 119 |
| Operating Profit | 1 | 2 | 2 | 5 | 4 | 5 | 8 | 12 | 12 |
| OPM % | 4.2% | 6% | 7% | 16% | 9% | 10% | 10% | 9% | 9% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| PBT | 0 | 0 | 1 | 4 | 4 | 4 | 6 | 9 | 9 |
| Tax % | 28% | 29% | 27% | 26% | 25% | 13% | 32% | 26% | — |
| Net Profit | 0 | 0 | 1 | 3 | 3 | 3 | 4 | 6 | 7 |
| EPS in Rs | 1.25 | 1.5 | 1.5 | 0.59 | 0.43 | 0.5 | 0.63 | 0.97 | 1.03 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 8% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.5 | 8 | 11 | 11 | 33 | 33 |
| Reserves | 5 | 5 | 6 | 3 | 21 | 25 | 6 | 13 |
| Borrowings | 8 | 9 | 17 | 16 | 7 | 6 | 11 | 22 |
| Other Liabilities | 3 | 10 | 5 | 21 | 10 | 15 | 22 | 39 |
| Total Liabilities | 16 | 24 | 29 | 48 | 49 | 57 | 72 | 106 |
| Fixed Assets | 2 | 5 | 6 | 7 | 7 | 12 | 12 | 15 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 14 | 19 | 23 | 41 | 42 | 44 | 60 | 92 |
| Total Assets | 16 | 24 | 29 | 48 | 49 | 57 | 72 | 106 |
Cash Flow
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | -3 | 3 | -6 | 2 | -9 | 8 | -4 | -4 |
| Investing | -1 | -3 | -2 | -1 | 1 | -6 | 0 | -4 |
| Financing | 4 | 0 | 7 | -1 | 8 | -2 | 4 | 9 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Free Cash Flow | -4 | 0 | -8 | 1 | -9 | 2 | -4 | -8 |
| CFO/OP | -225 | 177 | -268 | 41 | -206 | 185 | -31 | -37 |
Ratios
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 153 | 132 | 215 | 192 | 197 | 155 | 148 |
| Inventory Days | 21 | 52 | 72 | 212 | 130 | 149 | 128 | 110 |
| Days Payable | 18 | 122 | 58 | 218 | 76 | 92 | 98 | 93 |
| Cash Conversion Cycle | 115 | 83 | 146 | 208 | 246 | 254 | 186 | 165 |
| Working Capital Days | 62 | 7 | 74 | 117 | 221 | 181 | 124 | 103 |
| ROCE % | — | 12% | 10% | 23% | 15% | 11% | 16% | 18% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view JFL Life Sciences insights
58 extracted metrics + investor summaries across FY19–FY26.
Documents
1
Appointment
26 Aug - AGM approved reappointment of MD and two independent directors for five-year terms starting 2027. 26 Aug - AGM approved reappointment of MD and two independent directors for five-year terms starting 2027.
2
Appointment
26 Aug - AGM reappointed MD, whole-time director, and two independent directors for five-year terms from 2027. 26 Aug - AGM reappointed MD, whole-time director, and two independent directors for five-year terms from 2027.
3
Appointment
26 Aug - AGM reappointed MD, WTD, and two independent directors for five-year terms starting 2027. 26 Aug - AGM reappointed MD, WTD, and two independent directors for five-year terms starting 2027.
4
Appointment
26 Aug - AGM reappointed Managing Director, Whole-time Director, and two Independent Directors for five-year terms. 26 Aug - AGM reappointed Managing Director, Whole-time Director, and two Independent Directors for five-year terms.
5
General Updates
26 Aug - AGM re-appointed Managing Director, Whole-time Director, and two Independent Directors for five-year terms starting 2027. 26 Aug - AGM re-appointed Managing Director, Whole-time Director, and two Independent Directors for five-year terms starting 2027.
Frequently Asked Questions about JFL Life Sciences
What does JFL Life Sciences Ltd do?
Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]
Where is JFL Life Sciences Ltd (JFLLIFE) listed?
JFL Life Sciences Ltd trades as JFLLIFE on the NSE.
Which sector does JFL Life Sciences Ltd belong to?
JFL Life Sciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of JFL Life Sciences Ltd?
JFL Life Sciences Ltd has a market capitalisation of ₹70.28 Cr, which places it in the Small Cap band.
What is the PE ratio of JFL Life Sciences Ltd?
JFL Life Sciences Ltd trades at a PE ratio of 10.34, against a book value of ₹13.9 per share.
What is the 52-week high and low of JFL Life Sciences Ltd?
Over the last 52 weeks JFL Life Sciences Ltd has traded between ₹8.55 and ₹15.4.
Does JFL Life Sciences Ltd pay dividends?
JFL Life Sciences Ltd has a dividend yield of 2.35%.
What is the Return on Equity (ROE) of JFL Life Sciences Ltd?
JFL Life Sciences Ltd reported a return on equity of 10.54%. Its debt-to-equity ratio is 0.48.
Company Information
Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JFLLIFE.md for JFL Life Sciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.